JP7309212B2 - 新規な乳酸菌およびその応用 - Google Patents

新規な乳酸菌およびその応用 Download PDF

Info

Publication number
JP7309212B2
JP7309212B2 JP2020536979A JP2020536979A JP7309212B2 JP 7309212 B2 JP7309212 B2 JP 7309212B2 JP 2020536979 A JP2020536979 A JP 2020536979A JP 2020536979 A JP2020536979 A JP 2020536979A JP 7309212 B2 JP7309212 B2 JP 7309212B2
Authority
JP
Japan
Prior art keywords
disease
formulation
mice
preventing
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020536979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021509811A5 (https=
JP2021509811A (ja
Inventor
イン－チェン ツァイ
フイ－ユ ホアン
チエン－チェン ウー
ヂィ－シン シュー
Original Assignee
ベネド バイオメディカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベネド バイオメディカル カンパニー リミテッド filed Critical ベネド バイオメディカル カンパニー リミテッド
Publication of JP2021509811A publication Critical patent/JP2021509811A/ja
Publication of JP2021509811A5 publication Critical patent/JP2021509811A5/ja
Application granted granted Critical
Publication of JP7309212B2 publication Critical patent/JP7309212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020536979A 2018-01-05 2019-01-04 新規な乳酸菌およびその応用 Active JP7309212B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614296P 2018-01-05 2018-01-05
US62/614,296 2018-01-05
PCT/CN2019/070494 WO2019134690A1 (en) 2018-01-05 2019-01-04 A novel lactic acid bacteria and its applications

Publications (3)

Publication Number Publication Date
JP2021509811A JP2021509811A (ja) 2021-04-08
JP2021509811A5 JP2021509811A5 (https=) 2022-01-06
JP7309212B2 true JP7309212B2 (ja) 2023-07-18

Family

ID=67144146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536979A Active JP7309212B2 (ja) 2018-01-05 2019-01-04 新規な乳酸菌およびその応用

Country Status (7)

Country Link
US (1) US11938156B2 (https=)
EP (1) EP3735456B1 (https=)
JP (1) JP7309212B2 (https=)
CN (1) CN111868229B (https=)
ES (1) ES2986025T3 (https=)
TW (1) TWI705136B (https=)
WO (1) WO2019134690A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110305821B (zh) * 2019-08-28 2019-12-17 鲁东大学 副干酪乳杆菌配合car-t细胞治疗应用
JP7195714B2 (ja) * 2020-10-19 2022-12-26 曽根ファーム株式会社 炎症性腸疾患用組成物
CN110892940A (zh) 2019-11-20 2020-03-20 内蒙古伊利实业集团股份有限公司 副干酪乳杆菌k56在缓解肠道炎症方面的新应用
AU2021291569A1 (en) * 2020-06-16 2022-10-20 Md Healthcare Inc. Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from lactobacillus paracasei
CN114504599A (zh) * 2020-11-16 2022-05-17 内蒙古伊利实业集团股份有限公司 副干酪乳杆菌et-22在抗衰老、提高先天免疫方面的新应用
CN117860789A (zh) * 2020-11-16 2024-04-12 内蒙古伊利实业集团股份有限公司 副干酪乳杆菌k56在抗衰老、提高先天免疫方面的新应用
KR102606636B1 (ko) * 2021-01-29 2023-11-29 주식회사 농협사료 근감소증 예방 또는 개선 효과를 갖는 바실러스 벨레젠시스 및 이의 용도
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用
KR20230085279A (ko) * 2021-12-06 2023-06-14 엠테라파마 주식회사 락토바실러스 파라카제이 nk112, 실새삼 추출물 및 새삼 추출물을 포함하는 인지기능 및 장기능 장애의 예방 또는 치료용 조성물
WO2024086963A1 (en) * 2022-10-24 2024-05-02 Bened Biomedical Co., Ltd. Lactic acid bacterium and method for preventing or minimizing exercise-induced muscle damage
CN116064314B (zh) * 2022-11-01 2024-05-31 江苏省农业科学院 一株副干酪乳杆菌及其在制备发酵黑莓汁中的应用
CN116617273A (zh) * 2023-07-13 2023-08-22 微康益生菌(苏州)股份有限公司 副干酪乳杆菌lc86在制备用于预防、缓解或治疗与衰老相关的肌肉萎缩的产品中的应用
CN119950560A (zh) * 2025-03-10 2025-05-09 杭州百芮生物科技有限公司 乳酸菌菌株组合物在制备用于舒缓情绪以及促进神经元生长的组合物中的应用
CN120310715B (zh) * 2025-06-18 2025-10-24 宁波大学 一株具有改善抑郁功效的益生菌及其微生态制剂和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015146916A1 (ja) 2014-03-24 2015-10-01 大塚製薬株式会社 新規ラクトバチラス・パラカゼイ株

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
WO2010103132A1 (es) * 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
DK2411027T3 (en) * 2009-03-25 2015-01-19 Chr Hansen As USING a probiotic ADJUSTING body weight
CN104673700A (zh) * 2013-11-29 2015-06-03 晨晖生物科技股份有限公司 乳酸菌株及引物组
JP6305085B2 (ja) 2014-02-06 2018-04-04 キヤノン株式会社 Ｘ線撮影装置及びその制御方法
EP3067058A1 (en) * 2015-03-13 2016-09-14 Farmagens Health Care Srl Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids
ITUB20152376A1 (it) * 2015-07-07 2017-01-09 Alfasigma Spa Lactobacillus paracasei per la produzione di acido linoleico coniugato, preparazioni nutrizionali e farmaceutiche che lo comprendono e loro uso
TWI592487B (zh) 2016-10-05 2017-07-21 益福生醫股份有限公司 新穎副乾酪乳桿菌副乾酪亞種ｋ５６
JP7303811B2 (ja) 2017-12-19 2023-07-05 デュポン ニュートリション バイオサイエンシーズ エーピーエス 認知的及び精神的健康のためのプロバイオティクス

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015146916A1 (ja) 2014-03-24 2015-10-01 大塚製薬株式会社 新規ラクトバチラス・パラカゼイ株

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG, M.-C.，Prevention of hypertension-induced vascular dementia by Lactobacillus paracasei subsp. paracasei NTU 101-fermented products，Pharmaceutical Biology，2017年，Volume 55, Issue 1，P. 487-496

Also Published As

Publication number Publication date
EP3735456C0 (en) 2024-04-10
EP3735456A4 (en) 2021-09-29
EP3735456A1 (en) 2020-11-11
CN111868229B (zh) 2024-06-18
US20210085731A1 (en) 2021-03-25
US11938156B2 (en) 2024-03-26
ES2986025T3 (es) 2024-11-08
EP3735456B1 (en) 2024-04-10
TW201930585A (zh) 2019-08-01
JP2021509811A (ja) 2021-04-08
WO2019134690A1 (en) 2019-07-11
CN111868229A (zh) 2020-10-30
TWI705136B (zh) 2020-09-21

Similar Documents

Publication Publication Date Title
JP7309212B2 (ja) 新規な乳酸菌およびその応用
JP7038202B2 (ja) 新規な乳酸菌およびその用途
Al-Tawaha et al. Potential benefits of Lactobacillus plantarum as probiotic and its advantages in human health and industrial applications: A review
RU2563525C2 (ru) Пробиотическая композиция для применения в лечении воспаления кишечника
JP4521687B2 (ja) プロバイオティクス、プロピオニバクテリウム・イエンセニー７０２
JP5632289B2 (ja) 高いシュウ酸分解能を有する乳酸菌
KR102224072B1 (ko) 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
JP7280069B2 (ja) 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
KR102084825B1 (ko) 유아의 과도한 울음용 프로바이오틱
WO2011111734A1 (ja) 乳酸菌含有製剤
JP2020505031A (ja) 新規乳酸菌およびその応用
JP2022517754A (ja) 菌株、組成物および使用方法
JP5945092B2 (ja) 中性脂肪低減剤
JP7724223B2 (ja) 抗酸化剤として使用するためのプロバイオティクス組成物
JP7738071B2 (ja) ケストースを用いたアトピー皮膚炎の改善効能および腸内マイクロバイオーム調節
JP2024156916A (ja) 抑うつ症状改善剤及びそれを含む組成物
JP2022520904A (ja) うつ病及び不安障害の予防、改善又は治療効能を有するキムチ乳酸菌ラクトバチルスサケイ
Kumar et al. Development of antioxidant rich fruit fortified probiotic buttermilk (lassi) using lactobacillus rhamnosus culture
TWI721082B (zh) 新穎乳酸菌及其應用
JP6178088B2 (ja) Ｍ２マクロファージ分化誘導剤
JP5815105B2 (ja) 中性脂肪低減剤
JP5851242B2 (ja) チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および／または改善用の飲食品および医薬品
JP2023091935A (ja) ラクトコッカス属乳酸菌を含むストレス反応軽減剤
WO2023234166A1 (ja) 抗てんかん用組成物
JP2024033784A (ja) 腸内細菌叢改善用組成物、認知機能に関するバイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7309212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150